Clinical Trial

Ketamine for Methamphetamine Use Disorder

Study acronym: KMD
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD. The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).
Protocol Amendment History 1 change
critical Enrollment closed, study ongoing 2026-08-05
Trial Details
NCT Number NCT06496750
Lead Sponsor University of Texas Southwestern Medical Center
Conditions Substance Use Disorders, Substance Use, Methamphetamine Abuse
Enrollment 120 participants
Start Date 2024-09-11
Primary Completion 2026-08 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-11